Oza, Amit M. and Lorusso, Domenica and Oaknin, Ana and Safra, Tamar and Swisher, Elizabeth M. and Bondarenko, Igor M. and Huzarski, Tomasz and Klat, Jaroslav and Póka, Róbert and Viola, Luciana S. and Tankersley, Chris and Maloney, Lara and Goble, Sandra and Unger, Caro and Giordano, Heidi and Kristeleit, Rebecca S. (2017) ARIEL4: An International, Multicenter, Randomized Phase 3 Study of the PARP Inhibitor Rucaparib vs Chemotherapy in Germline or Somatic BRCA1- or BRCA2-Mutated, Relapsed, High-Grade Ovarian Carcinoma. Journal of Clinical Oncology, 35 (15). TPS5603- TPS5603. ISSN 0732-183X (Print) ; 1527-7755 (Electronic) ; 0732-183X (Linking)
|
Text
Rucaparib_AOza_Poster_ASCO2017.pdf Download (350kB) | Preview |
Abstract
Описание In high-grade ovarian cancer, including fallopian tube and primary peritoneal cancers, approximately 18% of patients have tumors with a germline BRCA1 or BRCA2 mutation and approximately 7% of patients have tumors with a somatic BRCA1 or BRCA2 mutation1• The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib has demonstrated efficacy in tumors with homologous recombination deficiency (HRD), including a BRCA1 or BRCA2 mutation2-5–In cells with HRD, PARP inhibition results in accumulation of double-strand ...
| Item Type: | Article |
|---|---|
| Subjects: | Oncology |
| Divisions: | Departments > Department of Oncology and Medical Radiology |
| Depositing User: | Елена Шрамко |
| Date Deposited: | 07 Sep 2017 12:33 |
| Last Modified: | 07 Sep 2017 12:44 |
| URI: | http://repo.dma.dp.ua/id/eprint/1924 |
Actions (login required)
 |
View Item |
